HomeMarketsSharesAdaptive Biotechnologies Corporation

Trade Adaptive Biotechnologies Corporation - ADPT CFD

Market is not available at the momentMarket information is presented
as of 2026-11-13T20:47:37+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.2
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02226 %
(-$0.45)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.00)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


0.00004%
Overnight funding adjustment time22:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin50.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close29.34
Open28.71
1-Year Change98.27%
Day's Range28.18 - 29.17

Trade Adaptive Biotechnologies Corporation - ADPT

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Adaptive Biotechnologies Corp revenues increased 57% to $154.3M. Net loss increased 42% to $207.3M. Revenues reflect Sequencing revenue segment increase of 90% to $78.9M, Development revenue segment increase of 32% to $75.4M. Higher net loss reflects Research and development - Balancing increase of 19% to $128.3M (expense), General and administrative - Balancing increase of 47% to $59.7M (expense).

Latest shares articles

What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026
Amazon's USD 220bn bet: how record AI spending could reshape the company
Amazon plans about USD 220bn of capex in 2026. We look at AWS, profitability, debt, valuation and the key catalysts and risks for AMZN shares.
10:50, 6 November 2026
Wall Street sign beside the marble facade of the New York Stock Exchange building, with American flags flying from the exterior
US midterms: the end of uncertainty could give Wall Street direction
Markets dislike uncertainty and volatility tends to rise ahead of the vote, but once the results are known, indices may be able to set a clearer direction.
13:28, 29 October 2026
BAE Systems stock forecast
BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready